The field of rheumatology presents a unique challenge because of the thought processes involved in making decisions and diagnoses. During my fellowship training and as part of obtaining my master’s degree, I discovered a profound lack of high-quality research studies in pediatric uveitis. Now, I dedicate my research to improving the visual outcomes of children with chronic, noninfectious uveitis using interventions that decrease vision loss and blindness.
In the past, there were no valid measures of uveitis outcomes, which led to my development of the only questionnaire that assesses vision-related function and quality of life in children with the condition. The Effects of Youngsters’ Eyesight on QOL (EYE-Q) is now part of clinical outcome measurements used to characterize the impact of uveitis on children’s lives.
Through my research, I identify risk factors for uveitis development, specifically in children with juvenile idiopathic arthritis. I accomplish this by discovering biomarkers in tears and by using genetic associations.
I work to standardize the approach clinicians use to evaluate uveitis outcomes, including assessments of the impact of uveitis on quality of life and functioning. This information then helps improve treatment outcomes.
Throughout my career, I have received several grants from organizations like Cincinnati Children’s Hospital Medical Center, the National Institutes of Health, and other ophthalmology and rheumatology foundations. In my continuing work, I lead initiatives to improve screening, monitoring and treatment of children with juvenile idiopathic arthritis and uveitis.
MD: University of Santo Tomas.
Residency: University of Illinois at Chicago, Chicago, IL.
Fellowship: Hospital for Special Surgery, New York, NY.
MS in Clinical Investigation: Weill Graduate School of Medical Sciences of Cornell University, New York, NY.
Juvenile idiopathic arthritis; juvenile idiopathic arthritis-associated uveitis; chronic pediatric non-infectious uveitis
Uveitis; juvenile idiopathic arthritis; biomarkers; visual outcomes; quality of life
Cincinnati Children's strives to accept a wide variety of health plans. Please contact your health insurance carrier to verify coverage for your specific benefit plan.
Therapeutic potential of JAK inhibitors in juvenile idiopathic arthritis-associated uveitis. Expert Review of Clinical Immunology. 2023; 19:689-692.
New and Updated Recommendations for the Treatment of Juvenile Idiopathic Arthritis-Associated Uveitis and Idiopathic Chronic Anterior Uveitis. Arthritis Care and Research. 2023; 75:975-982.
Screening, Monitoring, and Treating Children With Juvenile Idiopathic Arthritis-associated Uveitis: Visualizing Better Outcomes. The Journal of rheumatology. 2023; 50:300-303.
Alternative Biologic Therapy in Children Failing Conventional TNFα Inhibitors for Refractory, Noninfectious, Chronic Anterior Uveitis. American Journal of Ophthalmology. 2022; 244:183-195.
Relapse and Remission in Children With Chronic Noninfectious Uveitis Treated With Methotrexate. The Journal of rheumatology. 2022; 49:1289-1291.
AAPOS Pediatric Uveitis Committee: Pediatric uveitis cases—a multidisciplinary approach to management challenges. Journal of American Association for Pediatric Ophthalmology and Strabismus. 2022; 26:e68.
Comprehensive Assessment of Quality of Life, Functioning, and Mental Health in Children With Juvenile Idiopathic Arthritis and Noninfectious Uveitis. Arthritis Care and Research. 2022; 74:1311-1320.
Ophthalmic sequelae and psychosocial impact in pediatric ebola survivors. EClinicalMedicine. 2022; 49:101483.
2021 American College of Rheumatology Guideline for the Treatment of Juvenile Idiopathic Arthritis: Therapeutic Approaches for Oligoarthritis, Temporomandibular Joint Arthritis, and Systemic Juvenile Idiopathic Arthritis. Arthritis and Rheumatology. 2022; 74:553-569.
2021 American College of Rheumatology Guideline for the Treatment of Juvenile Idiopathic Arthritis: Recommendations for Nonpharmacologic Therapies, Medication Monitoring, Immunizations, and Imaging. Arthritis Care and Research. 2022; 74:505-520.